BXCL701, first-in-class oral activator of systemic innate immunity pathway, combined with pembrolizumab (Keytruda) in men with metastatic castration-resistant prostate cancer (mCRPC).

Authors

Rahul Raj Aggarwal

University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Rahul Raj Aggarwal , Dan Costin , Jingsong Zhang , Lawrence Ivan Karsh , Diane I. Healey , Mark David Linch , Sreenivas Adurthi , Daniel Peter Petrylak , Vince O'Neill , Paul Monk III

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype—Phase 2a interim results.

First Author: Scott T. Tagawa

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results.

First Author: Jingsong Zhang

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results.

First Author: Karim Fizazi

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.

First Author: Rahul Raj Aggarwal